Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Leads, implantable devices
Implantable cardioverter defibrillators (ICD)
Cardiac resynchronization therapy devices (CRT)
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
Clinical decision support
Johnson and Johnson
January 05, 2017
Global Thrombectomy Devices Market to Exceed $1 Million by 2022
January 5, 2017 — A new report published by Allied Market Research forecasts that the global...
March 09, 2015
Boston Scientific Announces Agreement With Johnson & Johnson to Resolve Guidant Litigation
March 9, 2015 — Boston Scientific Corp.
January 05, 2012
U.K. Clears Rivaroxaban as First Fixed Dose, Once-Daily Anticoagulant Tablet for Stroke, AF, DVT
January 5, 2011 – Bayer HealthCare's oral anticoagulant tablet Xarelto (rivaroxaban) has been approved for use in the...
November 16, 2011
Rivaroxaban Used in Combination with Standard Therapy Reduced Cardiovascular Death
November 16, 2011 – Johnson & Johnson Pharmaceutical Research & Development announced that adding oral...
June 16, 2011
Cordis Discontinues Cypher Stent, Halts Development of Nevo Stent
Cordis announced it will cease production of the Cypher sirolimus-eluting stent, the first drug-eluting stent (DES) to...
November 16, 2010
Rivaroxaban Significantly Reduces Stroke Risk in AF Patients
November 16, 2010 – Results from the ROCKET AF trial showed that rivaroxaban given once daily is superior at reducing...
October 04, 2010
Micrus Joins Codman Neurovascular
October 4, 2010 - Johnson and Johnson has completed the acquisition of Micrus Endovascular, a developer and...
Scranton Gillette Communications
. All Rights Reserved.
Terms and Conditions